What was recalled
The U.S. Food and Drug Administration (FDA) has officially announced a Class I recall for specific dialysis catheters manufactured by Bard Access Systems, Inc. This action, dated August 10, 2026, involves a significant range of products under the Bard brand name. Specifically, the recall targets two primary product lines: the DuoGlide Short-Term Straight Dialysis Catheter and the DuoGlide Short-Term Curved Extension Dialysis Catheter. Additionally, a single model from the Niagara line, the Niagara Dual-Lumen Short-Term Curved Extension Dialysis Catheter, is included in this recall effort. It is important to note that this is classified as a downstream recall associated with Class I recall RES 98777, indicating that while Bard Access Systems, Inc. is the manufacturer being recalled, the issue may be linked to broader supply chain or regulatory findings.
The scope of this recall is precise and covers multiple Reference (REF) numbers, each corresponding to different configurations of these medical devices. The affected DuoGlide Straight models include REF 5625150, REF 5625200, REF 5625240, and REF 5625300. For the curved extension variants, the recall lists REF 5626120, REF 5626150, REF 5626200, and REF 5626240. Finally, the Niagara Dual-Lumen catheter with REF 5766200 is also subject to this recall. While the FDA record does not explicitly state the total number of units involved in this specific batch, the extensive list of lot numbers suggests a widespread distribution that required careful tracking.
These devices were distributed across a vast geographic area within the United States. According to the official report, the products reached patients and healthcare facilities in 48 states, the District of Columbia, and Puerto Rico. The states included are Florida, Illinois, Ohio, Virginia, Maryland, Texas, Wisconsin, Georgia, Tennessee, Indiana, South Carolina, North Carolina, Michigan, Pennsylvania, Oregon, Oklahoma, Arizona, Mississippi, New Jersey, Alabama, California, Colorado, Massachusetts, Nevada, Idaho, Missouri, Louisiana, Washington, Kentucky, Iowa, New Hampshire, New York, Kansas, Hawaii, Nebraska, Minnesota, Montana, Wyoming, Arkansas, Rhode Island, West Virginia, Utah, Delaware, Connecticut, Maine, North Dakota, New Mexico, South Dakota, and the District of Columbia. The inclusion of Puerto Rico in this distribution pattern highlights the national scale of this medical device recall.
If you or a loved one has undergone dialysis procedures recently, it is crucial to verify whether the specific catheter used falls within these parameters. Healthcare providers are typically responsible for identifying the exact Reference numbers and lot codes used during treatment. However, patients should remain informed about the scope of this recall, which spans from the East Coast to the West Coast, ensuring that no region is left without awareness of this potential safety issue.
The hazard, explained
This recall involves a Class I medical device, which represents the FDA’s highest level of urgency. In plain terms, a Class I classification means that using this product is very likely to cause serious injury or even death. The specific items in question are short-term dialysis catheters manufactured by Bard Access Systems, Inc. These devices are designed to be inserted into a large vein, typically in the neck or chest, to provide reliable access for hemodialysis treatments. While the official recall notice does not explicitly detail the mechanical failure mode, Class I recalls for central venous catheters generally stem from critical structural defects that compromise the device’s integrity during use.
To understand why this is dangerous, it helps to look at how these catheters function under pressure. Dialysis requires blood to be pumped out of the body, filtered through a machine, and returned at relatively high flow rates. The catheter must withstand significant internal pressure and physical manipulation. If the device has a manufacturing defect—such as a weak bond between its components, a flaw in the material that makes it brittle, or an incomplete seal—it can fail catastrophically. This might manifest as the catheter breaking off inside the patient’s vein, leaking blood into surrounding tissues, or allowing air to enter the bloodstream (an embolism). Each of these scenarios is life-threatening and requires immediate emergency medical intervention.
The fact that this is a "downstream recall" linked to RES 98777 suggests that the root cause may be traced back to a broader quality control issue or a specific batch of raw materials used in production. Even if the defect is subtle, it can lead to severe complications for patients who rely on these catheters for their survival. Dialysis patients often have compromised vascular access and underlying health conditions, making them particularly vulnerable to any device failure. A breach in sterility could lead to serious bloodstream infections, while a structural break could cause blockages in the heart or lungs. Because the harm is so severe, the FDA has mandated that these devices be removed from use immediately, regardless of whether they appear intact on the outside.
It is important to note that this recall covers a wide range of specific Reference (REF) numbers and lot codes, indicating that the potential issue is not isolated to a single type or size but affects multiple configurations of the DuoGlide and Niagara product lines. The defect does not necessarily present visible signs to the naked eye; a catheter can look perfectly normal while harboring a critical internal flaw. This invisibility is precisely why regulatory oversight is so vital. Patients cannot inspect these devices for safety at home. The risk lies entirely in the device’s ability to perform its function safely within the body, and when that ability is compromised by a Class I defect, the consequence is not merely inconvenience—it is a direct threat to life.
Who is most at risk
To understand who is truly at risk here, we first need to look past the abstract category of "medical device" and focus on the specific individuals who rely on these products for survival. The Bard Access Systems DuoGlide and Niagara lines recalled in this Class I notification are not general-purpose tools; they are specialized short-term dialysis catheters. This distinction is critical because it immediately narrows the field of affected individuals to those with end-stage renal disease (ESRD) or acute kidney failure who require temporary but immediate vascular access for hemodialysis. These patients are not merely "users" in a casual sense; they are dependent on this equipment for life-sustaining treatment. The risk is therefore concentrated entirely within a vulnerable clinical population that is already managing significant health challenges.
The primary group at risk consists of patients currently undergoing or scheduled for short-term hemodialysis sessions. Because these catheters are designed for short-term use, they are typically implanted in individuals who have lost kidney function suddenly (acute kidney injury) or those with chronic kidney disease who do not yet have a permanent arteriovenous fistula or graft ready for use. The hazard associated with this Class I recall is the most severe classification possible, indicating a situation where use of the device could cause serious adverse health consequences or death. For a dialysis patient, this means that the very pathway used to filter their blood—bypassing their failing kidneys entirely—is compromised. If the catheter fails due to the underlying defect prompting this recall, it could lead to catastrophic bleeding, infection, or the inability to deliver necessary dialysis treatments.
Within this group, elderly patients and those with fragile vascular health are particularly vulnerable. Dialysis patients often have comorbid conditions such as diabetes, hypertension, or peripheral artery disease, which make their blood vessels more delicate and prone to complications. A failure in the catheter’s structural integrity could lead to vessel perforation or thrombosis (blood clots), risks that are exponentially higher for someone whose immune system may already be compromised by kidney disease. Furthermore, because this is a downstream recall linked to RES 98777, it suggests a systemic issue with the device's performance that affects the reliability of the entire supply chain distributed across major states including Florida, Texas, California, and New York. The individuals at risk are not just those who have the catheter in place today; they include anyone who received treatment from healthcare facilities in these distribution areas during the relevant timeframe. Since the remedy is not yet stated, the uncertainty adds a layer of psychological and physical stress to an already precarious health situation, leaving patients and their care teams in a waiting period where the safety of their primary life-support access is in question.
How to tell if you have the recalled item
Identifying whether you possess a recalled medical device requires careful attention to specific details printed on the packaging and the product itself. Because this recall involves Bard Access Systems, Inc., you must first confirm that the brand is indeed "Bard." The affected products are primarily the DuoGlide Short-Term Straight Dialysis Catheter and the DuoGlide Short-Term Curved Extension Dialysis Catheter, along with the Niagara Dual-Lumen Short-Term Curved Extension Dialysis Catheter. These items are not generic; they are specific medical supplies often used in clinical settings for dialysis procedures. If you are a patient or a caregiver looking at these devices at home, check the label on the sterile packaging for the Bard logo and the product name.
The most critical step in verification is checking the Reference number (REF) printed on the box. The recall impacts multiple specific REF codes. You should look for any of the following REF numbers: 5625150, 5625200, 5625240, 5625300, 5626120, 5626150, 5626200, 5626240, 5766200, and 5575150. If your device has one of these REF numbers, it is potentially part of this recall, but you must also check the lot number to be certain. The FDA classifies this as a Class I recall, which is the most serious type, indicating that use of the product could cause serious adverse health consequences or death. Therefore, precision in identification is vital.
Once you have identified the correct REF number, you must examine the Lot number and the Expiration Date. The recall affects specific lots with expiration dates ranging from August 2026 to July 2027. For example, if you have REF 5625150, check for lots such as REKS1082, REKS2493, or REKV2899. If you have REF 5625200, look for lots like REKQ3365 or RELP1350. The expiration date is printed alongside the lot number on the label. It is important to note that even if a device has not yet expired, it is still subject to this recall due to the downstream nature of the Class I classification (RES 98777). Do not rely on the expiration date alone to determine safety.
If you are unable to locate the REF or Lot number on the packaging, or if the label is damaged, do not attempt to use the device. Instead, contact Bard Access Systems directly for assistance in identifying your product. You can also consult the FDA’s official recall database using the specific reference numbers listed above. Since these devices were distributed across many states including Florida, Illinois, Ohio, Virginia, Texas, and others, local pharmacy or hospital records may help you trace the origin of the device if you are unsure where it came from.
What to do — step by step
If you or a healthcare provider have any of the Bard Access Systems DuoGlide or Niagara dialysis catheters listed above, your immediate priority is to ensure patient safety through proper verification and cessation of use. Because this is a Class I recall issued by the FDA, it represents the most serious type of recall classification, indicating that use of the product could cause serious adverse health consequences or death. Therefore, you must not wait for symptoms to appear before taking action. The first concrete step is to stop using these devices immediately if they are still in inventory or have been implanted but not yet fully integrated into long-term care plans where replacement might be medically contraindicated. For healthcare facilities, this means quarantining the specific lots mentioned in the recall notice to prevent accidental administration or implantation.
The next critical step is accurate identification. You must carefully check the packaging and the device itself against the specific Reference numbers (REF) and Lot numbers provided in the official FDA announcement. The affected items include REF 5625150, 5625200, 5625240, 5625300, 5626120, 5626150, 5626200, 5626240, and 5766200, among others. Look for the UDI-DI and specific Lot codes such as REKS1082, REKU1654, or RELP1350, which correspond to expiration dates ranging from August 2026 through July 2027. If you are a patient, do not attempt to remove the catheter yourself. Dialysis catheters are inserted into large veins and require sterile, surgical removal to avoid severe bleeding or infection. Contact your nephrologist or dialysis center immediately with the lot information in hand.
However, there is an important gap in the current public information regarding the remedy. The official recall facts for this specific event do not state whether Bard Access Systems is offering a repair, a replacement unit, or a refund. This silence is significant and requires proactive communication on your part. You should contact Bard Access Systems customer service directly to inquire about their specific resolution plan for these defective units. Simultaneously, report the issue to the FDA’s MedWatch program. This allows regulatory officials to track the full extent of the distribution and ensures that if other patients are affected, they can be notified. Do not assume the manufacturer will reach out proactively; in Class I recalls involving medical devices, the burden is often on the provider or patient to initiate the closure of the loop.
Finally, document everything. Keep records of your communication with Bard Access Systems, your healthcare provider, and any reports filed with the FDA. If you are a healthcare facility, update your inventory management systems to flag these lots permanently. If you are a patient, keep copies of all medical notes stating that the device was recalled and removed or monitored. This documentation is vital for future medical care, as it ensures that any new providers understand why this specific device is no longer in use and helps protect you from any potential liability or confusion regarding your treatment history. Stay calm but be persistent; your diligence ensures that this safety issue is fully resolved.
Your refund, repair, or replacement options
When you first see the details of a Class I medical device recall, it is completely natural to feel a surge of anxiety, particularly when the official remedy is not explicitly detailed in the initial notification. In this specific instance regarding Bard Access Systems, Inc., the FDA record for the DuoGlide and Niagara catheters does not list a standard consumer-facing remedy such as a direct refund, a mail-in repair kit, or an automatic replacement program. This absence of explicit instructions can be confusing, but it is important to understand that Class I recalls are typically initiated by the manufacturer to correct violations that pose the lowest risk of serious adverse health consequences, or where the probability of serious injury is remote. The fact that this is a "downstream recall" linked to previous actions (RES 98777) suggests that the issue may be procedural, logistical, or related to specific batch controls rather than an immediate, catastrophic failure of every single unit produced.
Because the remedy is not stated in the public FDA alert, you should not assume that you are entitled to a check in the mail or that you need to take drastic action on your own. For medical devices like dialysis catheters, which are strictly regulated and typically implanted or inserted by healthcare professionals, the "remedy" is almost always managed through the clinical supply chain rather than the patient directly. The primary course of action here is to contact the manufacturer, Bard Access Systems, Inc., directly. While the specific phone number or email address is not provided in this summary, you can locate their official customer service or medical device reporting contact information on the Bard Access Systems website or by calling the FDA MedWatch hotline at 1-800-FDA-1088 for guidance on how to proceed.
If you are a patient who has received one of these catheters, your most critical step is to consult with the healthcare provider who performed the procedure. They have access to the full recall notice and will know if any specific clinical follow-up or device exchange is required. If you are a healthcare facility administrator or distributor, you must immediately quarantine any remaining stock matching the listed Reference Numbers (such as 5625150, 5625200, etc.) and Lot Expiration dates. Do not use these devices for new patients until you have received clear instructions from Bard Access Systems. The lack of a stated remedy in this specific alert does not mean the issue is minor; it simply means the resolution path is professional-to-professional. Please reach out to the manufacturer’s official support channels to confirm whether any corrective action, such as a return for credit or a technical inspection, is necessary for your specific inventory or usage situation.
What can happen if you ignore it
When a Class I recall is issued by the FDA, it represents the most serious category of safety alert. This classification means that using or being exposed to the recalled product is reasonably likely to cause serious adverse health consequences or death. Ignoring this specific recall for the Bard Access Systems DuoGlide and Niagara dialysis catheters is not a matter of minor inconvenience; it is a direct threat to your physiological stability. Because these devices are designed for short-term vascular access in dialysis patients, they are subjected to significant mechanical stress and are in constant contact with blood. Any defect that compromises their integrity can lead to immediate, life-altering complications.
The primary danger lies in the potential for device failure under clinical conditions. Dialysis catheters must maintain precise structural integrity to withstand the high flow rates required during treatment while remaining flexible enough to avoid damaging delicate vein walls. If a defect exists in the catheter material or construction—such as delamination, cracking, or improper sealing of the lumens—you risk several catastrophic outcomes. The most immediate fear is embolism, where a fragment of the device breaks off and travels through the bloodstream to the heart or lungs, potentially causing blockage, stroke, or cardiac arrest. Another critical risk is uncontrolled hemorrhage. If the catheter fails during removal or while in use, it may not seal properly, leading to severe bleeding at the insertion site that can be difficult to manage quickly.
Beyond acute physical trauma, there is a substantial risk of systemic infection. Dialysis patients are often immunocompromised, making them exceptionally vulnerable to bloodstream infections (bacteremia or sepsis). A defective catheter may have microscopic pathways for bacteria to enter the body or may lack the proper antimicrobial coating necessary to prevent colonization. Once an infection takes hold in the bloodstream, it can rapidly progress to septic shock, a condition where blood pressure drops dangerously low and organs begin to fail. This is particularly dangerous because dialysis patients already have compromised vascular access points that serve as direct highways for pathogens.
Furthermore, ignoring the recall means you are operating without the safety net of manufacturer verification. You cannot know if your specific unit has a microscopic flaw that only manifests under pressure or over time. The consequences of waiting are not just about the immediate failure of the device; they involve the long-term health of your vascular access sites. Damage caused by a defective catheter can ruin veins that were intended for future use, leaving you with fewer options for life-sustaining treatments down the line. In the context of dialysis, where every milliliter of blood flow matters and every infection is a battle for survival, continuing to use a recalled device is an unacceptable gamble with your life.